Mar 22, 2023 InvoX Pharma’s F-star announces licence agreement with Takeda for second novel next-generation immuno-oncology bispecific antibody »
Dec 6, 2022 F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress »
Nov 7, 2022 F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research »
Aug 11, 2022 F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights »
Jul 20, 2022 F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody »
Jun 23, 2022 invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs »
May 10, 2022 F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update »
May 2, 2022 F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022 »
Apr 8, 2022 F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022 »
Mar 14, 2022 F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update »
Mar 2, 2022 F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022 »
Jan 20, 2022 F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3 »
Dec 7, 2021 F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021 »
Nov 12, 2021 F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference »
